Physician profile
Molly Jane Rittenhouse
NPI 1447913892
$2,371.16
in general payments reported to CMS, 2019-2025
17 companies · $706 in 2025
The $706 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $48.86 · 2023: $425 · 2024: $1,191 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $793.50 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $485.82 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $283.72 | 2023-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $141.54 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $131.04 | 2024 | Voquezna |
| Celgene Corporation | $100.49 | 2023-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $85.26 | 2023-2025 | Entyvio, Eohilia |
| Pfizer INC. | $50.57 | 2025 | |
| Madrigal Pharmaceuticals | $49.83 | 2025 | Rezdiffra |
| Genzyme Corporation | $46.36 | 2023-2025 | |
| Ardelyx, INC. | $45.65 | 2023-2025 | Ibsrela |
| Organon LLC | $35.96 | 2024 | |
| Pharmacosmos Therapeutics INC. | $35.36 | 2024-2025 | Monoferric |
| Qol Medical, LLC | $32.76 | 2025 | Sucraid |
| Lilly USA, LLC | $19.85 | 2024 | Omvoh |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $18.41 | 2025 | Vowst |
| Evoke Pharma, INC. | $15.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Rittenhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.